SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US OTC > Biotechs >

Advanced Environmental Petroleum (AEPP)

AEPP RSS Feed
Add AEPP Price Alert      Hide Sticky   Hide Intro
Moderator: reaper247, B0tt0M WaTcH3R, Eltp, fuzzymcilwoods, FIN85, ninersax
Search This Board: 
Last Post: 5/24/2017 1:24:53 AM - Followers: 126 - Board type: Free - Posts Today: 8

 

BIOTECH Merger in Action


April 24 Interview with CEO Michael Redman
 


On April 6, 2017, in connection with the change of control of the Company, Mr. Kistler resigned as the Company’s sole director, executive officer and other positions and Mr. Redman was appointed a director and our chief executive officer and president and J. Donald Payne as a director and our Secretary and chief accounting officer of the Company.



Verified Company Profile  4/10/2017
Email: mredman@oncolixbio.com
 

AEPP (Advanced Environmental Petroleum Producers) Oncolix, Inc. has become the controlling shareholder

https://www.sec.gov/Archives/edgar/data/1574061/000147793217001787/aepp_sc13d.htm
https://www.sec.gov/Archives/edgar/data/1584137/000147793217001656/aepp_8k.htm



AEPP enters into a SPA (Share Purchase Agreement) with Oncolix, Inc. 


Initial agreement was made on March 7, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74041605

http://ih.advfn.com/p.php?pid=nmona&article=74093500

Merger expected to be finalized on or around April 3, 2017
http://ih.advfn.com/p.php?pid=nmona&article=74157198

AEPP UPDATE:

Change of control of AEPP has been filed with the Florida Secretary of State showing Oncolix CEO

Michael Redman and Oncolix director, Donald Payne as controlling officers of AEPP.

 
AEPP Security Details
Share Structure
  Market Value1 $3,571,704 a/o Apr 07, 2017
Authorized Shares 500,000,000 a/o Mar 30, 2017
Outstanding Shares 93,911,633 a/o Apr 04, 2017
  -Restricted Not Available
  -Unrestricted Not Available
  Held at DTC Not Available
  Float 33,311,633 a/o Apr 06, 2017
  Par Value Not Available
Transfer Agent(s) Verified by Transfer Agent
VStock Transfer LLC
Shareholders
Shareholders of Record 101 a/o Apr 06, 2017

 


Zero outstanding debt

"approximately $111,928 of the $315,000 purchase price will be utilized by the Seller to pay all outstanding indebtedness and financial obligations of the Company so that immediately following the closing of the Share Acquisition (the “ SPAClosing ” ), the Company will have no outstanding indebtedness and/or other financial obligations."
http://ih.advfn.com/p.php?pid=nmona&article=74093500 

April 3, 2017 SPA closing date expected
Due to unanticipated circumstances, the mailing did not occur. As a result, we filed Amendment No. 1 to the Original Filing on March 21, 2017, ( “ Amendment No.1 and together with the Original Filing, collectively, the “ Information Statement ” ), anticipate March 22, 2017 to be the new mailing date and the date of the Board Change and the SPA Closing to occur on or about April 3, 2017 (but in no event earlier than 10 days after the actual mailing date).

Filings from Oncolix after closing will be expected within 4 business days which will detail merger.
Consequently, many more news events will follow with Oncolix releasing details of their business and status of Prolanta as it goes through FDA clinical trials.


 

Who is Oncolix, Inc.?

https://oncolixbio.com

April 2017 Company Presentation:
https://nebula.wsimg.com/8b544fcbb6f5bf5fb52c1c7e5a69eb81?AccessKeyId=D34B304F5C474C27E878&disposition=0&alloworigin=1

POST ACQUISITION INTERVIEW WITH CEO MICHAEL REDMAN

https://www.youtube.com/watch?v=Ox6n1HH8v_0&feature=youtu.be
 

Oncolix, Inc. (Oncolix) is a clinical-stage bio-pharmaceutical company based in Houston, Texas. We are developing Prolanta™, a targeted therapeutic protein for the treatment of ovarian, breast and other cancers. The Company has a US FDA-cleared IND to commence human testing of Prolanta™ in our first indication, the treatment of ovarian cancer.  This clinical trial is expected to begin in late 2015. Prolanta™ is a prolactin receptor antagonist that has demonstrated significant efficacy in xenograft models through a unique mechanism of action, autophagy (see Our Science). In addition to ovarian cancer, there is strong preclinical evidence Prolanta™ will be effective in breast, prostate and other cancers.   

The FDA has also approved the designation of 
Prolanta™ as an Orphan Drug for the treatment of ovarian cancer, which may allow an accelerated regulatory approval by the FDA, reduced filing fees, federal tax credits and marketing exclusivity. 

Prolanta is currently in FDA clinical trials phase 1. 
https://clinicaltrials.gov/ct2/show/NCT02534922

Oncolix received Orphan Drug Status for their developmental drug Prolanta.
http://www.bizjournals.com/houston/news/2013/04/24/oncolix-poised-to-start-phase-i-trials.html

8 U.S. Patents have been awarded in the development of Prolanta
http://oncolixbio.com/patents.html

 

PATENTS

The eight US Patents issued to Oncolix are listed in the following table. Non-US patents or applications are not listed.

Patent Number Issue Date Issued To Title
US 7,115,556 03 OCT 2006 Oncolix Use of Anti-Prolactin Agents to Treat Proliferative Conditions
US 7,201,905 10 APR 2007 Oncolix Bi-Functional Cancer Treatment Agents
US 7,339,027

US 8,304,381
4 MAR 2008

6 NOV 2012
Oncolix Human Prolactin Antagonist-Angiogenesis Inhibitor Fusion Proteins
US 7,632,809 15 DEC 2009 Oncolix Multimeric Ligands with Enhanced Stability
US 8,648,046

US 8,754,035
11 FEB 2014

17 JUN 2014
Oncolix Compositions and Methods for Visualizing and Eliminating Cancer Stem Cells
US 8,754,031 17 JUN 2014 Oncolix Use of Prolactin Receptor Antagonists in Combination with an Agent that Inactivates the HER2/neu Signaling Pathway

Notable excerpt from company website
Our initial focus is ovarian cancer, and we have an FDA-cleared Investigational New Drug (IND) application to commence a Phase I human trial. Based on our preclinical evidence of expected efficacy, the FDA has also granted Prolanta™ Orphan Drug status for the treatment of ovarian cancer.  Our collaborators at The University Texas MD Anderson Cancer Center developed the efficacy data in ovarian cancer, which was published in Cell Reports (see Scientific Publications). These researchers demonstrated that Prolanta™ has a novel mechanism of action, induced autophagy) against ovarian cancer, and also demonstrated the synergy of Prolanta™ with other chemotherapy drugs. See Ovarian Cancer and Prolanta™.

 

 

The Oncolix Team

Management

\

\

Board Members

\

\

\

Company Advisors

\

\

\



 



  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
AEPP
Current Price
Volume:
Bid Ask Day's Range
AEPP News: Quarterly Report (10-q) 05/15/2017 06:12:06 AM
AEPP News: Initial Statement of Beneficial Ownership (3) 04/28/2017 11:44:59 AM
AEPP News: Initial Statement of Beneficial Ownership (3) 04/24/2017 02:16:03 PM
AEPP News: Statement of Beneficial Ownership (sc 13d) 04/17/2017 04:04:57 PM
AEPP News: Amended Statement of Changes in Beneficial Ownership (4/a) 04/14/2017 10:29:25 AM
PostSubject
#4458  Sticky Note It's official. No Reverse Split. fuzzymcilwoods 05/15/17 04:41:18 PM
#4166  Sticky Note Now we know who is the ex Ceo B0tt0M WaTcH3R 04/27/17 07:38:54 PM
#3811  Sticky Note VERY IMPRESSIVE "ONCOLIX" APRIL 2017_COMPANY_PRESENTATION: https://nebula.wsimg. Rat Fink 04/23/17 02:31:27 PM
#3419  Sticky Note Reverse split is definitely happening. The wording in ninersax 04/11/17 10:53:11 PM
#4749   I wish someone could tell me why that BLight1911 05/24/17 01:24:53 AM
#4748   Do you have a snickers bar in your minivan? reaper247 05/24/17 01:10:26 AM
#4747   There again, too many words to keep my ninersax 05/24/17 12:58:04 AM
#4746   That would depend on the circumstances. reaper247 05/24/17 12:53:33 AM
#4745   Lol...I bet you are a pole smoker. ninersax 05/24/17 12:08:38 AM
#4744   Sure. That would be easy. Below me. reaper247 05/24/17 12:07:27 AM
#4743   Reverse split...ha! That's two words ninersax 05/24/17 12:05:47 AM
#4741   Too long of a post to read and ninersax 05/23/17 11:54:01 PM
#4740   It was #3 on the breakout board because reaper247 05/23/17 11:52:30 PM
#4739   "AEPP" SHAREHOLDERS "HOLDING" THEIR SHARES!!!_ONLY_1%_OF_FLOAT_TRADED_TODAY!!! Rat Fink 05/23/17 11:51:44 PM
#4738   BUT IT WAS #3 on the breakout boards---- 10daytradehailchaser 05/23/17 10:37:53 PM
#4737   Easy fix...click on "Hide Sticky Notes". They were DayDreeming 05/23/17 10:28:08 PM
#4736   Add R\S BS to the list DayDreeming 05/23/17 10:03:53 PM
#4735   APPEARS "AEPP" BUYERS WANTS CHEAPIES WHILE_"SHAREHOLDERS"_PATIENTLY_"HOLDIN Rat Fink 05/23/17 09:50:47 PM
#4734   Need the value of those 8 patents to retiredtech 05/23/17 09:43:16 PM
#4733   Big money is investing in Oncolix and there reaper247 05/23/17 09:35:54 PM
#4732   You called it right on time..calm before the tmcfo 05/23/17 06:02:16 PM
#4731   I see that.. looks like .02 will be B0tt0M WaTcH3R 05/23/17 02:25:15 PM
#4730   500K bid @ .02 is curious ... ;-) molee 05/23/17 02:06:18 PM
#4729   Whopping 2 trades today. Just no interest in ninersax 05/23/17 01:09:23 PM
#4728   APRIL 2017 "ONCOLIX" COMPANY PRESENTATION: https://nebula.wsimg.com/8b544fcbb6f5 Rat Fink 05/23/17 10:40:05 AM
#4727   When Oncolix decides to be publicly traded, then ninersax 05/23/17 10:35:51 AM
#4726   M.D. ANDERSON'S PRE-CLINCAL TRIAL "ONCOLIX" PROLANTA (G129R) http://nebula.wsim Rat Fink 05/23/17 10:33:25 AM
#4725   I agree- still possible. If you look up 10daytradehailchaser 05/23/17 10:32:49 AM
#4724   Although there is a lot of potential, it's 10daytradehailchaser 05/23/17 10:30:38 AM
#4723   VERY IMPRESSIVE "ONCOLIX" CEO INTERVIEW (4/24/17)>>> https://www.youtube.com/wa Rat Fink 05/23/17 10:29:54 AM
#4722   And do a reverse split. Can't leave out ninersax 05/23/17 10:28:09 AM
#4721   Why? 10daytradehailchaser 05/23/17 10:27:48 AM
#4720   HOUSTON, TX, April 6, 2017 / -- ONCOLIX, DayDreeming 05/23/17 10:11:32 AM
#4719   MAY 15-17 "ONCOLIX" PARTICIPATED IN US/CHINA_INNOVATION_&_INVESTMENT_SUMMIT!!! h Rat Fink 05/23/17 10:03:45 AM
#4718   Big money buying up AEPP...lol There's no interest in ninersax 05/23/17 10:01:56 AM
#4717   INVENTOR OF "PROLANTA" ALSO INVENTED "SOMAVERT"_SOLD_BY_PFIZER!!! https://www.on Rat Fink 05/23/17 09:57:52 AM
#4716   BIOPHARMA COMPANY "ONCOLIX" HAS "8" U.S. PATENTS!!! https://www.oncolixbio.com/o Rat Fink 05/23/17 09:35:54 AM
#4715   More eyes more attention B0tt0M WaTcH3R 05/23/17 09:14:58 AM
#4713   # 3 on the Break Out board... getReady 05/23/17 08:36:06 AM
#4710   Big things ahead for "AEPP"! I'm holding_all_my_shares! Rat Fink 05/22/17 11:38:49 PM
#4709   Plan of operation investorshub.advfn.com/uimage/uploads/2017/5/22/ywmnqI B0tt0M WaTcH3R 05/22/17 11:35:15 PM
#4708   Have never seen it but it sure makes retiredtech 05/22/17 11:32:37 PM
#4707   Its good to see some conversation and excitement Sungod95 05/22/17 11:20:41 PM
#4706   Imagine if ex ceo and other big B0tt0M WaTcH3R 05/22/17 11:12:23 PM
#4705   This is the thing for me. reaper247 05/22/17 11:09:06 PM
#4704   Agree! The M. D. Anderson pre-clinical_trial_conclusions_indicates_that! Rat Fink 05/22/17 10:54:35 PM
#4703   If you will see the pic of G129R B0tt0M WaTcH3R 05/22/17 10:51:53 PM
#4702   Yes, with huge potential revenue this will run B0tt0M WaTcH3R 05/22/17 10:49:36 PM
#4701   M.D. ANDERSON'S PRE-CLINCAL TRIAL "ONCOLIX" PROLANTA (G129R) http://nebula.wsim Rat Fink 05/22/17 10:46:14 PM
#4700   I completely agree. I think this stock is dabullishbear 05/22/17 10:42:55 PM
#4699   I think lots of eyes on this, just B0tt0M WaTcH3R 05/22/17 10:41:19 PM
#4698   I'm really surprised she's not in on this dabullishbear 05/22/17 10:39:23 PM
#4697   Lol... That's funny but yes I would love it B0tt0M WaTcH3R 05/22/17 10:38:28 PM
#4696   Imagine if Oncolix put value on every patent B0tt0M WaTcH3R 05/22/17 10:37:30 PM
PostSubject